Solveig Tiepolt1, Swen Hesse2,3, Marianne Patt2, Julia Luthardt2, Matthias L Schroeter4, Karl-Titus Hoffmann5, David Weise6, Hermann-Josef Gertz7, Osama Sabri2,3, Henryk Barthel2. 1. Department of Nuclear Medicine, University of Leipzig, Liebigstr. 18, 04103, Leipzig, Germany. solveig.tiepolt@medizin.uni-leipzig.de. 2. Department of Nuclear Medicine, University of Leipzig, Liebigstr. 18, 04103, Leipzig, Germany. 3. Integrated Research and Treatment Center (IFB) Adiposity Diseases, Leipzig, Germany. 4. Clinic for Cognitive Neurology & Max Planck Institute for Human Cognitive & Brain Sciences, University of Leipzig, Leipzig, Germany. 5. Department of Neuroradiology, University of Leipzig, Leipzig, Germany. 6. Department of Neurology, University of Leipzig, Leipzig, Germany. 7. Department of Psychiatry, University of Leipzig, Leipzig, Germany.
Abstract
PURPOSE: [(18)F]FDG is a commonly used neuronal injury biomarker for early and differential diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose consumption. Early uptake of the Aβ tracer [(11)C]PiB on PET images is mainly determined by cerebral blood flow and shows a high correlation with [(18)F]FDG uptake. Uptake data for (18)F-labelled Aβ PET tracers are, however, scarce. We investigated the value of early PET images using the novel Aβ tracer [(18)F]FBB in the diagnosis of Alzhimers disease (AD). METHODS: This retrospective analysis included 22 patients with MCI or dementia who underwent dual time-point PET imaging with either [(11)C]PiB (11 patients) or [(18)F]FBB (11 patients) in routine clinical practice. Images were acquired 1 - 9 min after administration of both tracers and 40 - 70 min and 90 - 110 min after administration of [(11)C]PiB and [(18)F]FBB, respectively. The patients also underwent [(18)F]FDG brain PET imaging. PET data were analysed visually and semiquantitatively. Associations between early Aβ tracer uptake and dementia as well as brain atrophy were investigated. RESULTS: Regional visual scores of early Aβ tracer and [(18)F]FDG PET images were significantly correlated (Spearman's ρ = 0.780, P < 0.001). Global brain visual analysis revealed identical results between early Aβ tracer and [(18)F]FDG PET images. In a VOI-based analysis, the early Aβ tracer data correlated significantly with the [(18)F]FDG data (r = 0.779, P < 0.001), but there were no differences between [(18)F]FBB and [(11)C]PiB. Cortical SUVRs in regions typically affected in AD on early Aβ tracer and [(18)F]FDG PET images were correlated with MMSE scores (ρ = 0.458, P = 0.032, and ρ = 0.456, P = 0.033, respectively). A voxel-wise group-based search for areas with relatively higher tracer uptake on early Aβ tracer PET images compared with [(18)F]FDG PET images revealed a small cluster in the midbrain/pons; no significant clusters were found for the opposite comparison. CONCLUSION: Early [(18)F]FBB and [(11)C]PiB PET brain images are similar to [(18)F]FDG PET images in AD patients, and these tracers could potentially be used as biomarkers in place of [(18)F]FDG. Thus, Aβ tracer PET imaging has the potential to provide biomarker information on AD pathology and neuronal injury. The potential of this approach for supporting the diagnosis of AD needs to be confirmed in prospective studies in larger cohorts.
PURPOSE: [(18)F]FDG is a commonly used neuronal injury biomarker for early and differential diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose consumption. Early uptake of the Aβ tracer [(11)C]PiB on PET images is mainly determined by cerebral blood flow and shows a high correlation with [(18)F]FDG uptake. Uptake data for (18)F-labelled Aβ PET tracers are, however, scarce. We investigated the value of early PET images using the novel Aβ tracer [(18)F]FBB in the diagnosis of Alzhimers disease (AD). METHODS: This retrospective analysis included 22 patients with MCI or dementia who underwent dual time-point PET imaging with either [(11)C]PiB (11 patients) or [(18)F]FBB (11 patients) in routine clinical practice. Images were acquired 1 - 9 min after administration of both tracers and 40 - 70 min and 90 - 110 min after administration of [(11)C]PiB and [(18)F]FBB, respectively. The patients also underwent [(18)F]FDG brain PET imaging. PET data were analysed visually and semiquantitatively. Associations between early Aβ tracer uptake and dementia as well as brain atrophy were investigated. RESULTS: Regional visual scores of early Aβ tracer and [(18)F]FDG PET images were significantly correlated (Spearman's ρ = 0.780, P < 0.001). Global brain visual analysis revealed identical results between early Aβ tracer and [(18)F]FDG PET images. In a VOI-based analysis, the early Aβ tracer data correlated significantly with the [(18)F]FDG data (r = 0.779, P < 0.001), but there were no differences between [(18)F]FBB and [(11)C]PiB. Cortical SUVRs in regions typically affected in AD on early Aβ tracer and [(18)F]FDG PET images were correlated with MMSE scores (ρ = 0.458, P = 0.032, and ρ = 0.456, P = 0.033, respectively). A voxel-wise group-based search for areas with relatively higher tracer uptake on early Aβ tracer PET images compared with [(18)F]FDG PET images revealed a small cluster in the midbrain/pons; no significant clusters were found for the opposite comparison. CONCLUSION: Early [(18)F]FBB and [(11)C]PiB PET brain images are similar to [(18)F]FDG PET images in ADpatients, and these tracers could potentially be used as biomarkers in place of [(18)F]FDG. Thus, Aβ tracer PET imaging has the potential to provide biomarker information on AD pathology and neuronal injury. The potential of this approach for supporting the diagnosis of AD needs to be confirmed in prospective studies in larger cohorts.
Authors: Jan Booij; Javier Arbizu; Jacques Darcourt; Swen Hesse; Flavio Nobili; Pierre Payoux; Sabina Pappatà; Klaus Tatsch; Zuzana Walker; Marco Pagani Journal: Eur J Nucl Med Mol Imaging Date: 2013-07 Impact factor: 9.236
Authors: Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings Journal: Lancet Neurol Date: 2014-06 Impact factor: 44.182
Authors: Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe Journal: Eur J Nucl Med Mol Imaging Date: 2012-03-08 Impact factor: 9.236
Authors: Henryk Barthel; Julia Luthardt; Georg Becker; Marianne Patt; Eva Hammerstein; Kristin Hartwig; Birk Eggers; Bernhard Sattler; Andreas Schildan; Swen Hesse; Philipp M Meyer; Henrike Wolf; Torsten Zimmermann; Joachim Reischl; Beate Rohde; Hermann-Josef Gertz; Cornelia Reininger; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2011-05-06 Impact factor: 9.236
Authors: Philipp T Meyer; Sabine Hellwig; Florian Amtage; Christof Rottenburger; Ursula Sahm; Peter Reuland; Wolfgang A Weber; Michael Hüll Journal: J Nucl Med Date: 2011-02-14 Impact factor: 10.057
Authors: Juergen Dukart; Karsten Mueller; Annette Horstmann; Barbara Vogt; Stefan Frisch; Henryk Barthel; Georg Becker; Harald E Möller; Arno Villringer; Osama Sabri; Matthias L Schroeter Journal: Neuroimage Date: 2009-09-18 Impact factor: 6.556
Authors: Murat Bilgel; Lori Beason-Held; Yang An; Yun Zhou; Dean F Wong; Susan M Resnick Journal: J Cereb Blood Flow Metab Date: 2019-02-12 Impact factor: 6.200
Authors: Matthias Brendel; Jonas Schnabel; Sonja Schönecker; Leonie Wagner; Eva Brendel; Johanna Meyer-Wilmes; Marcus Unterrainer; Andreas Schildan; Marianne Patt; Catharina Prix; Nibal Ackl; Cihan Catak; Oliver Pogarell; Johannes Levin; Adrian Danek; Katharina Buerger; Peter Bartenstein; Henryk Barthel; Osama Sabri; Axel Rominger Journal: Eur J Nucl Med Mol Imaging Date: 2017-09-20 Impact factor: 9.236
Authors: Sonja Daerr; Matthias Brendel; Christian Zach; Erik Mille; Dorothee Schilling; Mathias Johannes Zacherl; Katharina Bürger; Adrian Danek; Oliver Pogarell; Andreas Schildan; Marianne Patt; Henryk Barthel; Osama Sabri; Peter Bartenstein; Axel Rominger Journal: Neuroimage Clin Date: 2016-10-08 Impact factor: 4.881